RPSA and cancer: To summarize, since IgG1-iS18 antibodies represent a promising tool for treating prion diseases, Alzheimer’s disease, or different types of cancers (Chetty et al., 2014; Rebelo et al., 2016), this indicates that the anti-LamR antibodies we used could have therapeutic potential in diseases associated with abnormalities in the PNS development and functioning.